Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Anavex Life Sciences Corp.

Latest From Anavex Life Sciences Corp.

Anavex Finds EXCELLENCE Trial To Be Ironically Named

A failure in children with Rett syndrome sees the company’s market value cut by more than a third.

Clinical Trials Commercial

Korea's AriBio Progresses Phase III Program For Oral Alzheimer's Contender

South Korean firm AriBio is planning to expand global Phase III trials for its oral Alzheimer’s disease candidate following an IND approval at home. Patient enrolment in a US trial began late last year.

Clinical Trials Neurology

Does Prothena Have A Best-In-Class Alzheimer’s Drug Waiting In The Wings?

More than 20 years since its forerunner tried to develop the first anti-amyloid drug, Prothena’s CEO tells Scrip about its hopes for producing a best-in-class subcutaneous treatment for Alzheimer’s disease.

Clinical Trials Neurology

Acadia’s Daybue Gets First Approval In Rett Syndrome

Daybue is the first drug approved to treat the rare neurodevelopmental disorder Rett syndrome, despite high clinical trial incidence of diarrhea. Product labeling includes clinician guidance for the side effect.

Approvals Rare Diseases
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Anavex Australia Pty Ltd.